Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study - PubMed (original) (raw)
Clinical Trial
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
Walter H Gotlieb et al. Lancet Oncol. 2012 Feb.
Abstract
Background: Targeting of VEGF is a potential therapeutic option in patients with malignant ovarian ascites. We present the final results of a multicentre study of the efficacy and safety of aflibercept, a potent inhibitor of both VEGF and placental growth factor, in the treatment of malignant ascites.
Methods: In this double-blind, placebo-controlled, parallel-group, phase 2 study, patients with advanced chemoresistant ovarian cancer and recurrent symptomatic malignant ascites were randomly assigned (1:1) via an interactive voice response system to either intravenous aflibercept (4 mg/kg every 2 weeks) or placebo, stratified by interval of time (≤ 2 weeks vs > 2 weeks) between the two most recent paracenteses before randomisation. Patients participated in the double-blind period (during which patients, investigators, and sponsor personnel were masked to treatment assignment) until they had a repeat paracentesis and for at least 60 days, and could also participate in an optional open-label period during which all patients received aflibercept. The primary efficacy endpoint was time to repeat paracentesis based on response during the double-blind period alone, and was analysed in the intention-to-treat population with censoring of patients who did not have a repeat paracentesis as of the last day of the double-blind period. Safety analyses included both double-blind and open-label periods. This study is registered at ClinicalTrials.gov, number NCT00327444.
Findings: 55 patients with a median of four (range two to 11) previous lines of chemotherapy were randomly assigned to receive placebo (n=26) or aflibercept (n=29). Mean time to repeat paracentesis was significantly longer with aflibercept than with placebo (55·1 [SE 7·3] vs 23·3 [7·7] days; difference 31·8 days, 95% CI 10·6-53·1; p=0·0019). In the aflibercept group, two patients did not need a repeat paracentesis during 6 months of double-blind treatment. The most common grade 3 or 4 treatment-emergent adverse events were dyspnoea (six [20%] aflibercept vs two [8%] placebo), fatigue or asthenia (four [13%] vs 11 [44%]), and dehydration (three [10%] vs three [12%]). The frequency of fatal gastrointestinal events was higher with aflibercept (three intestinal perforations) than with placebo (one intestinal fistula leading to sepsis).
Interpretation: This study shows the effectiveness of VEGF blockade in the reduction of malignant ascites, but confirms the significant clinical risk of fatal bowel perforation in this population of patients with very advanced cancer. VEGF blockade should be used with caution in advanced ovarian cancer with abdominal carcinomatosis, and the benefit-risk balance should be thoroughly discussed for each patient.
Funding: Sanofi Oncology.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
- VEGF Trap for the treatment of malignant ascites.
Becker G, Blum HE. Becker G, et al. Lancet Oncol. 2012 Feb;13(2):115-6. doi: 10.1016/S1470-2045(11)70394-1. Epub 2011 Dec 20. Lancet Oncol. 2012. PMID: 22192728 No abstract available. - Gynecological cancer: True progress in ovarian cancer or just the tip of the iceberg?
Hutchinson L. Hutchinson L. Nat Rev Clin Oncol. 2012 Jan 17;9(2):65. doi: 10.1038/nrclinonc.2011.210. Nat Rev Clin Oncol. 2012. PMID: 22249444 No abstract available.
Similar articles
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators. Tannock IF, et al. Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4. Lancet Oncol. 2013. PMID: 23742877 Clinical Trial. - A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, Chamberlain D. Colombo N, et al. Gynecol Oncol. 2012 Apr;125(1):42-7. doi: 10.1016/j.ygyno.2011.11.021. Epub 2011 Nov 21. Gynecol Oncol. 2012. PMID: 22112608 Clinical Trial. - Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Paz-Ares L, et al. Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16. Lancet Oncol. 2012. PMID: 22341744 Clinical Trial. - Catumaxomab: in malignant ascites.
Frampton JE. Frampton JE. Drugs. 2012 Jul 9;72(10):1399-410. doi: 10.2165/11209040-000000000-00000. Drugs. 2012. PMID: 22676343 Review. - European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.
Stanel SC, Sjöberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F. Stanel SC, et al. ESMO Open. 2017 May 2;2(2):e000190. doi: 10.1136/esmoopen-2017-000190. eCollection 2017. ESMO Open. 2017. PMID: 28761750 Free PMC article. Review.
Cited by
- Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES, Wakabayashi M, Leong L. Han ES, et al. Curr Treat Options Oncol. 2013 Mar;14(1):22-33. doi: 10.1007/s11864-012-0220-6. Curr Treat Options Oncol. 2013. PMID: 23288484 Review. - Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome.
Lee JN, Solimando DA Jr, Waddell JA. Lee JN, et al. Hosp Pharm. 2013 Jan;48(1):14-22. doi: 10.1310/hpj4801-14. Hosp Pharm. 2013. PMID: 24421416 Free PMC article. - Sustained Improvement in a Metastatic Colon Cancer Patient with FOLFIRI-Aflibercept after FOLFOX Failure.
Aggarwal S. Aggarwal S. Case Rep Oncol. 2015 Nov 13;8(3):487-92. doi: 10.1159/000441413. eCollection 2015 Sep-Dec. Case Rep Oncol. 2015. PMID: 26668569 Free PMC article. - Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K, Rogozińska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Gaitskell K, et al. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3. Cochrane Database Syst Rev. 2023. PMID: 37185961 Free PMC article. - Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
Elit L, Hirte H. Elit L, et al. Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26. Onco Targets Ther. 2013. PMID: 23459506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical